As botanical alternatives to opioids gain mainstream traction, emergency physicians are confronting a clinical problem that defies standard overdose playbooks. Kratom — derived from Mitragyna speciosa, a Southeast Asian tree — is now appearing with increasing frequency in toxicology cases, and its complex pharmacology means the go-to opioid antidote, naloxone, may not reliably reverse its effects.
This narrative review published in Cureus synthesizes case reports, case series, observational studies, and prior reviews to map the toxicological profile of kratom. The plant's primary alkaloids — mitragynine and 7-hydroxymitragynine — act on mu-opioid receptors, producing respiratory depression, sedation, and other opioid-like toxidromes. However, the clinical response to naloxone is heterogeneous: some patients respond partially, others not at all, and a subset experience delayed or recurrent respiratory depression after an initial reversal appears successful. Product variability in alkaloid concentration, metabolite activity, and frequent co-ingestion of other substances compound the diagnostic and therapeutic challenge for clinicians determining appropriate observation windows and discharge timing.
Kratom occupies a particularly thorny regulatory and clinical gray zone. Sold legally in most U.S. states as a dietary supplement or tea, it is neither scheduled nor standardized, meaning alkaloid content varies widely by product lot and vendor. Prior research has established that 7-hydroxymitragynine — a minor constituent but potent mu-opioid agonist — is partly responsible for the opioid-like effects, while mitragynine itself has more complex, biased agonism properties. The delayed-recurrence phenomenon noted in this review parallels concerns seen with long-acting opioids like methadone, where a single naloxone dose gives false reassurance. This review is limited by its reliance on case-level evidence rather than controlled trials, and publication bias likely skews the literature toward severe presentations. Nonetheless, for clinicians and health-conscious adults using kratom for pain or withdrawal self-management, the finding that toxicity may evade standard antidotes represents an underappreciated safety signal.